ArticleBMC gastroenterology2026
Molecular subtyping of colorectal cancer based on inositol metabolism identifies PLCG2 as a key prognostic biomarker.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInositol metabolism, a crucial regulatory mechanism in cellular signaling, plays a pivotal role in colorectal cancer (CRC) tumorigenesis and progression. While multiple inositol-metabolizing enzymes have been implicated in CRC development, a systematic characterization of inositol metabolism-associated gene signatures and molecular subtyping based on these regulators remains unexplored.
methodsTranscriptomic profiles and clinical data of CRC patients were obtained from TCGA and GEO databases. Integrated transcriptomic analysis enabled the stratification of CRC into distinct inositol metabolism-associated molecular subtypes via unsupervised consensus clustering. An inositol metabolism-related prognostic signature was constructed using LASSO-Cox regression. The functional role of the key identified gene was validated through in vitro experiments.
resultsCRC was stratified into two distinct subtypes (Cluster 1 and Cluster 2) exhibiting significant heterogeneity in clinical outcomes, tumor microenvironment features, and therapeutic vulnerabilities. The Cluster 1 subtype demonstrated strong associations with microsatellite stability (MSS), cell cycle processes, MYC signaling, and better patient prognosis. In contrast, the Cluster 2 subtype was closely linked to microsatellite instability (MSI), epithelial-mesenchymal transition (EMT), and TGF-β signaling. Additionally, a low Inositol Score was associated with increased sensitivity to multiple chemotherapeutic and targeted agents. Notably, phospholipase C gamma 2 (PLCG2) was identified as a key discriminator between subtypes and a top prognostic biomarker. PLCG2 was upregulated in CRC tissues, and its knockdown significantly suppressed tumor cell proliferation and migration in vitro.
conclusionsThis study delineates novel inositol metabolism-based molecular subtypes in CRC, proposes PLCG2 as a promising prognostic biomarker and functional oncogene, and provides a conceptual framework for targeting inositol metabolism in clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.